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Amrita Krishnan,1 Joycelynne M. Palmer,2 John A. Zaia,3 Ni-Chun Tsai,2
Joseph Alvarnas,1 Stephen J. Forman1Randomized trials comparing autologous stem cell transplant (ASCT) to conventional chemotherapy have
demonstrated superior survival among HIV-negative ASCT patients with relapsed non-Hodgkin lymphoma
(NHL). Recent trials explored the feasibility of ASCT in the HIV setting. Although these studies have shown
that ASCT in HIV-positive NHL patients (HIVpos-NHL) is well tolerated, the impact of HIV infection on
long-term transplant outcome is not well characterized. Ongoing comparison of long-term survival following
ASCT in HIVpos-NHL patients and HIVneg-NHL patients will allow investigators to explore whether
there should be inclusion of HIVpos-NHL patients in ASCT trials. To study long-term outcomewe conducted
a single-institution matched case-controlled study in HIVpos-NHL patients (cases) and HIVneg-NHL patients
(controls). Twenty-nine patients with HIVpos-NHL were matched with HIVneg-NHL controls on sex, time to
ASCT, year of transplant, histology, age, disease status, number prior regimens, and conditioning regimen.
Nonrelapsemortality (NRM)was similar: 11% (95% confidence interval [CI]: 4%-28%) inHIVpos-NHLpatients
and 4% (95% CI: 1%-25%) in HIVneg-NHL controls (P 5 .18). Two-year disease-free survival (DFS) for the
HIVpos-NHL patients was 76% (95% CI: 62%-85%) and 56% (95% CI: 45%-66%) for the HIVneg-NHL controls
(P5 .33). Overall survival was also similar; the 2-year point estimates were 75% (95% CI: 61%-85%) and 75%
(95% CI: 60%-85%), respectively (P 5 .93), despite inclusion of more poor risk HIVpos-NHL patients. These
results provide further evidence that HIV status does not affect the long-term outcome of ASCT for NHL,
and therefore HIV status alone should no longer exclude these patients from transplant clinical trials.
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Although survival of HIV-infected patients has
increased since the advent of effective antiretroviral
therapy [1], AIDS-related malignancies remain a lead-
ing cause of mortality [2]. Prior to the development of
effective antiretroviral therapy, the prognosis for
patients with AIDS-related lymphoma (ARL) was
extremely poor. This was because of factors such as
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6/j.bbmt.2010.03.019highly aggressive histologies, and inability to tolerate
intensive chemotherapy because of poor hematologic
reserve and frequent opportunistic infections [3,4].
In the era of highly active antiretroviral (HAART)
therapy, treatment with standard doses of chemother-
apy such as R-CHOP (cyclophosphamide [Cy], doxo-
rubicin vincristine, prednisone, plus rituximab)
became possible for HIV-positive patients [5]. A phase
II trial of R-CHOP in 42 patients with ARL yielded
a complete remission rate of 77% and an estimated
2-year overall survival (OS) probability of 75% [5].
The authors of this trial emphasized that the response
rate (76%) and OS at 2 years (70%) were consistent
with the phase III GELA (Groupe d’Etude des Lym-
phomes de l’Adulte) trial where 399 HIV-negative el-
derly patients were randomized to receive R-CHOP or
CHOP alone as induction therapy [6]. Thus, in the
HAART era, response rates for HIVpos-NHL are
expected to be similar to HIVneg-NHL treated with
similar standard-dose chemotherapy.
Currently, it is unknown whether poor-risk
HIVpos-NHL patients who undergo high-dose
Biol Blood Marrow Transplant 16:1302-1308, 2010 1303HIV Status and Transplantationchemotherapy and autologous stem cell transplant
(ASCT) experience long-term outcomes that are sim-
ilar to HIVneg-NHL patients. Trials from our institu-
tion and European centers demonstrated feasibility
and safety of transplant in HIVpos- non-Hodgkin
lymphoma (NHL) [7,8]. The City of Hope was the
U.S. center that pioneered the use of hematopoietic
stem cell transplantation for HIV-positive patients.
Our trial, updated in 2008 to include 23 patients who
received either Cy BCNU Etoposide (CBV) or
radiation-based conditioning, reported a disease-free
survival (DFS) of 78% at 2 years, with a median
follow-up of 41 months [9]. Other multicenter trials
have echoed the feasibility of this approach. The
AIDS clinical trial group recently reported the results
from a multi-institutional trial that utilized busulfan
and Cy for conditioning, and among the 27 patients
enrolled, 20 went on to transplant with a 6-month
event-free survival (EFS) of 49.5% [8]. However,
many physicians still automatically consider HIV
status to be a barrier to transplant, and similarly,
transplant centers often exclude these patients from
their protocols.
We have now reached a time where some re-
searchers consider HIV to be a chronic illness that
should be treated as any other comorbidity. Many
patients with HIV infection live for many years and
no longer die of infectious causes. Nonetheless, they
remain susceptible to other risks such as cardiovascular
disease and malignancy. Given the greatly decreased
mortality associated with HIV infection, one must
question whether it is still justified to exclude
HIV-infected individuals from treatments that are the
standard of care for HIV-negative patients. Some
physicians in the solid-organ transplant literature
have gone so far as to say, ‘‘The HIV patients should
be considered no different than any other patient who
may have higher transplant risks than the average
patient, such as the African American, highly sensi-
tized, diabetic or older patients’’ [10,11]. Randomized
trials to investigate hematopoietic stem cell outcomes
based on HIV status will not be possible. However,
well-described retrospective studies of outcomes may
corroborate this bold assertion and hopefully convince
more physicians to offer transplant to HIV-positive
patients. To further investigate the impact of HIV
infection on ASCT, a single institution case-control
study of 29 HIVpos-NHL patients and 29 matched
HIVneg-NHL controls was performed.PATIENTS AND METHODS
The City of Hope (COH) observational research
transplant database identified a consecutive case series
of 29 HIVpos-NHL patients and 29 matched HIVneg-
NHL controls treated with ASCT between the years1998 and 2007. Patients were matched on sex, age at
ASCT 65 years, year of transplant 65 years, disease
status at ASCT, number of prior regimens of chemo-
therapy, time from NHL diagnosis to ASCT, condi-
tioning regimen, and histology. In situations where
more than 1 potential control was identified, the best
matched HIVneg-NHL control was selected. The
COH institutional review board approved the analysis
of these data. Pathology and pretransplant staging were
also reviewed at the COH. International Working
Group criteria (IWG) defined disease response
posttransplant, as some patients were treated prior to
implementation of revised response criteria [12].
Eligibility Criteria
The indications for ASCT included NHL in first
partial remission (PR), high-risk first remission (as
defined by the international prognostic index), or
relapsed disease. Standard transplant organ function
criteria were used to assess physiologic suitability for
ASCT. HIV-positive patients were required to have
a viral load \50,000copies/mL and to be free of
opportunistic infections for 1 year prior to ASCT.
Conditioning Regimen and Supportive Care
The choice of conditioning regimen was based
on institutional practice guidelines for NHL at the
time. Patients were conditioned primarily with
nonradiation-based conditioning of either CBV (Cy,
BCNU, Etoposide) or BEAM (BCNU, Etoposide,
Cytarabine, Melphalan).
Statistical Methods
Survival estimates were calculated based on the
Kaplan-Meier product-limit method, 95% confidence
intervals (CIs) were calculated using the logit transfor-
mation and the Greenwood variance estimate [13].
Patients who were alive at the time of analysis were cen-
sored at the last contact date. OS was measured from
transplant to death from any cause. DFS was defined
as time from transplant to recurrence, progression, or
death. The time to relapse/progression was defined as
time from transplant to recurrence or progression.
The cumulative incidence for relapse/progression was
computed treating a nonrelapse/progression death
event as a competing risk. Nonrelapse mortality
(NRM) was measured from transplant to death from
any cause other than disease relapse or disease progres-
sion. Differences between survival curves were assessed
by the log-rank test. Assessment of potential baseline
differences between the 2 groups was examined using
the Wilcoxon Rank Sum test for continuous variables
or Fisher’s exact test for categoric variables. The signif-
icance of patient, disease, and treatment features was
assessed using survival analysis and univariate Cox
regression analysis [14]. Univariate Cox proportional
Table 1. Patient, Disease, and Treatment Characteristics
Characteristic
HIV+ NHL*
(Case)
N 5 29
HIV2 NHL*
(Control)
N 5 29 p-Value†
Patient sex
Female 2 (7) 2 (7) .99
Male 27 (93) 27 (93)
Age at ASCT (years) 42 (11-68) 48 (21-65) .06
Histology
Diffuse large B cell 14 (48) 22 (76) —
Mediastinal large B cell 0 (0) 1 (3)
Marginal zone B cell 0 (0) 1 (3)
Immunoblastic large B cell 2 (7) 0 (0)
Burkitt lymphoma 11 (38) 0 (0)
Follicular lymphoma 0 (0) 4 (14)
Anaplastic large cell 2 (7) 1 (3)
Stage at diagnosis
I 1 (3) 4 (14) .41
II 1 (3) 2 (7)
III 8 (28) 6 (21)
IV 19 (66) 17 (58)
1304 Biol Blood Marrow Transplant 16:1302-1308, 2010A. Krishnan et al.hazard models were used to model time to event end-
points (eg, OS, DFS, relapse/progression, and NRM),
as a function of the prognostic variables. The list of
prognostic variables was determined from a literature
review that identified factors associated with survival
and/or disease relapse/recurrence in NHL patients
treated with ASCT. The variables included as part of
this assessment were: histopathologic subtype (diffuse
large B cell versus others), median number of prior
therapies (\2, $2), patient age at ASCT (\44 years,
$44 years), disease grade (intermediate versus others),
disease stage (I-II versus III-IV), disease status at the
time of ASCT (complete remission [CR]/PR versus
relapse/induction failure), presence of marrow involve-
ment at diagnosis (yes, no), and HIV status at ASCT
(positive, negative). Statistical significance was set at
the P\ .05 level.Bone marrow involvement
at diagnosis
Yes 8 (28) 9 (31) .74 (yes
versus no)
No 18 (62) 18 (62)
Unknown, test not done 3 (10) 2 (7)
Extranodal disease at diagnosis
Yes 20 (69) 18 (62) .56 (yes
versus no)
No 8 (28) 11 (38)
Test not done 1 (3) 0 (0)
Time from diagnosis to
ASCT (months)
11.7
(0.2-115.3)
12.6
(5.8-205.6)
.25
Number of prior regimens 2 (1-4) 2 (1-4) .33
Chemo sensitivity
Yes 23 (79) 27 (93) .10
No 6 (21) 2 (7)
Disease status at ASCT
CR/PR 20 (69) 20 (69) .61
Relapse 7 (24) 6 (21)
IF 2 (7) 3 (10)
ASCT conditioning regimen
FTBI/VP16/Cy 4 (14) 4 (14) .32
BCNU/VP16/Cy 25 (86) 22 (76)
BEAM 0 (0) 3 (10)
ASCT indicates autologous stem cell transplantation; CI, confidence in-
terval; NHL, non-Hodgkin lymphoma; CR, complete remission; PR, par-
tial remission, Cy, cyclophosphamide.
*Reported as number of patients (percent) or median (range).
†McNemar’s c2 test applied for categorical data; Wilcoxon Rank Sum
test applied for continuous data.RESULTS
Patient Characteristics
A consecutive case-series of 29 HIVpos-NHL pa-
tients and 29 matched HIVneg-NHL controls treated
with ASCT between the years of 1998 and 2007 were
included. Patient, disease, and treatment characteris-
tics for both groups are provided in Table 1. An assess-
ment of potential differences in disease and treatment
characteristics between the 2 groups showed no signif-
icant ‘‘baseline’’ differences with the exception of
disease grade. A larger proportion of HIVpos-NHL
patients were diagnosed with high-grade disease
(n 5 17, 59%) when compared to the HIVneg-NHL
controls (n 5 2, 7%). Both groups were comprised
primarily of male patients (n5 27, 93%), diffuse large
B cell lymphoma, and transplanted within the first year
post-NHL diagnosis. At the time of transplant, the
majority of patients had received a median of 2 (range:
1-4) prior regimens, were in CR/PR, and had chemo-
sensitive disease. Five patients were diagnosed with
HIV infection concomitant with the lymphoma diag-
nosis and started on antiretroviral therapy. With
regard to HIV status, the median CD4 count at study
entry was 153.5 (range: 25-620) and the viral load was
6500 (range: 730-32,000). Twenty-two patients had an
undetectable viral load at study entry. All patients in
the HIV cohort were on HAART at the time of trans-
plant; however, temporary interruption of therapy was
required in 13 patients.Outcomes
At the time of analysis the median follow-up for
HIVpos-NHL patients was 62.4 months (range:
0.7-123.3) and 48.4 months (range: 4.4-101.6) for the
HIVneg-NHL controls. The median number of days
to neutrophil engraftment (absolute neutrophil count[ANC] $500) was similar for both groups: 10 days
(range: 5-19) for HIVpos-NHL patients and 11 days
(range: 9-35) for HIVneg-NHL controls. NRM calcu-
lated using the Kaplan-Meier method were also simi-
lar: 11% in the HIV-positive patients and 4% in the
controls at 1 year (Figure 1). Although infectious com-
plications did differ between the 2 groups, with more
opportunistic infections seen in the HIV-positive
patients, this did not have an impact on survival
(Table 2). The major difference in infections was
incidence of opportunistic viral infections in the
HIV-positive group with 3 cases of cytomegalovirus
(CMV) viremia, 1 case of adenovirus viremia, and
1 case of varicella infection. HIV viral load was
Table 2. Summary of Outcomes Post-ASCT
Outcome
HIV+ NHL*
(Case)
N 5 29
HIV2 NHL*
(Control)
N 5 29
Engraftment
Days to reach ANC $ 500 10 (5-19) 11 (9-35)
Total number of pts experiencing
infection within 100 days: Grade $3†
16 10
Total number of infections 28 14
Bacterial 17 11
Fungal 0 1
Viral 1 1
OI (cmv, vzv) 4 0
Unclassified‡ 6 1
Progression/relapse
Yes 6 (21) 15 (52)
No 23 (79) 14 (48)
Number of death events
Alive 21 (72) 19 (66)
Dead 8 (28) 10 (34)
Causes of death
Disease progression/relapse 4 8
Other
Interstitial pneumonitis 0 1
Sepsis 1 0
Secondary malignancy, AML 1 1
Congestive heart failure 1 0
Unknown 1 0
ANC indicates absolute neutrophil count; NHL, non-Hodgkin lym-
phoma; AML, acute myelogenous leukemia.
*Reported as number of patients (percent) or median (range).
†All infections equal to or greater than grade 3 are included regardless
of attribution.
‡Unclassified 5 no organism could be isolated.
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Figure 2. Probability of disease-free survival by HIV status.
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ral load was 1600 (range: 52-149,680). Causes of death
in the HIV positive patients were primarily because of
relapsed lymphoma. DFS and OS were not signifi-
cantly different between the groups (see Figures 2
and 3). There were 8 deaths in the HIV-positive group:
4 from NHL, 1 from therapy-related acute leukemia, 1
from congestive heart failure, 1 from sepsis, and 1 out-
side death of unknown cause. In the HIV-negative
group there were 10 deaths: 8 from disease progression
or relapse, 1 from therapy-related acute leukemia, and
1 from interstitial pneumonitis.P
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Figure 1. Probabiliy of nonrelapse death.We further examined the impact of HIV status on
survival and relapse/progression by univariate Cox re-
gression analysis. The results of this analysis showed
that HIVpos-NHL patients were not at increased
risk for death or relapse/progression post-ASCT
when compared to HIVneg-NHL patients (Table 3,
Figure 4). Of the factors tested, only disease status at
transplant consistently emerged as a prediction of
outcome.DISCUSSION
ASCT has long been accepted as the optimal ther-
apy for poor risk NHL. The original randomized trials
(eg, the PARMA trial) excluded patients with HIV in-
fection, but served to position ASCT as the standard of
care for relapsed NHL by demonstrating superior
DFS and OS when compared with conventional sal-
vage therapy [15]. Prior to this time, it was appropriate
to exclude patients with HIV infection, as that was be-
fore the start of effective antiretroviral therapy. At that
time, pre-1996, HIV-infected patients often had se-
vere hematologic impairment and increased mortality
because of infections. Post-1996, the use of HAART
changed the prognosis of HIV infection [1]. There-
fore, in this era, it was appropriate to question prior
paradigms. The first paradigm was that patients
with HIV associated lymphomas should be treatedS
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Figure 3. Probability of overall survival by HIV status.
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Figure 4. Cumulative proability of relapse/progression.
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sus low-dose m-BACOD trial had formed the basis for
this theory. In that trial, patients treated on the stan-
dard chemotherapy dose arm had more hematologic
toxicity, without any difference in OS or DFS com-
pared to the reduced dose arm [16]. However, because
this trial took place between 1991 and 1994, the
patients were not on HAART. In the HAART era,
patients have been treated with what is considered
standard of care for HIV-negative NHL patients,
R-CHOP. The French reported complete response
rates of 77% and 2-year survival of 75% in a series of
61 patients with HIV-associated NHL [5]. These
results are comparable to those of HIV-negative
patients treated with R-CHOP, and therefore, in the
era of HAART, disproves the paradigm that less
chemotherapy leads to more favorable outcome in
the treatment of HIV NHL.
The paradigm of HIV infection limiting the feasi-
bility and tolerability of stem cell mobilization and
ASCT was also challenged in the era of HAART. In-
vestigators from France were the first to report onTable 3. Results of Univariate Analysis
Overall Survival
Parameter Value N
No. of
Events
Hazard Rate
Ratio (95% CI) P-Va
Age at HCT 0: < 44 58 16 Baseline .35
1: $ 44 1.62 (0.59-4.46)
Histology at HCT 0: Others 58 16 Baseline .0
1: DLBCL 4.64 (1.05-20.42)
NHL grade 0: Others 58 16 Baseline 0.12
1: Intermediate 2.73 (0.78-9.58)
Stage at diagnosis 0: I - II 58 16 Baseline 0.84
1: III - IV 1.17 (0.26-5.14)
Extranodal disease at
diagnosis
0: No 57 15 Baseline 0.57
1: Yes 0.74 (0.26-2.08)
Number of prior regimens 0: <2 58 16 Baseline 0.13
1: $2 4.71 (0.62-35.69)
Disease status at HCT 0: CR/PR 58 16 Baseline 0.0
1: RL/IF 2.71 (1.02-7.24)
HIV status 0: Negative 58 16 Baseline 0.91
1: Positive 1.06 (0.40-2.81)
HCT indicates hematopoietic cell transplant; NHL, non-Hodgkin lymphoma; C
plete remission; PR, partial remission.the use of ASCT in a group of 14 patients. All the pa-
tients engrafted, but 8 died, 6 from progressive NHL.
Nonetheless, despite these high relapse rates, this was
the first study to demonstrate the feasibility of ASCT
in HIV-infected individuals [17]. The COH expanded
upon this experience in a larger series of patients, all
with chemosensitive disease [18]. This initial series
also demonstrated that treatmeant-related mortality
was low in the HIV-positive patient, and that durable
remissions from the lymphoma could be obtained. A
recently published multicenter trial from 20 centers
in Europe provided further corroboration [19]. The
trial enrolled patients from 1999 and included a total
of 68 patients. The NRM was 7.5%, mainly because
of bacterial infections. The progression-free survival
(PFS) was 56%. The series included 8 patients with
chemorefractory disease, and subgroup analysis, not
surprisingly found that patients not in CR or with
refractory disease at the time of transplant had a poorer
PFS. The Italian cooperative group on AIDS and
tumors also showed a high PFS of 76% in the 21
patients who underwent transplant [20]. The NRM
is similar to the PARMA trial of HIV-negative patients
undergoing ASCT, where there was a 6% toxic death
rate: 4 patients died of infection and 1 patient from
cardiac toxicity [15]. Of the 29 patients in each cohort
in our series, the number who developed infections was
small: 16 in the HIV-positive patients and 10 in the
HIV-negative group. The total number of infections
is detailed in Table 2; as expected, several patients
had more than 1 infection. Because of the small num-
ber of patients in each cohort, the impact of the type of
infection, for example, eg bacterial, on mortality, could
not be demonstrated.
The aforementioned studies certainly are sugges-
tive that the outcome is similar for HIV-positiveDisease-Free Survival Relapse/Progression
lue
No. of
Events
Hazard Rate
Ratio (95% CI) P-Value
No. of
Events
Hazard Rate
Ratio (95% CI) p-Value
20 Baseline .68 16 Baseline .63
1.20 (0.50-2.91) 1.27 (0.47-3.41)
4 20 Baseline .06 16 Baseline .19
2.82 (0.94-8.44) 2.13 (0.69-6.61)
20 Baseline .17 16 Baseline .22
2.04 (0.74-5.61) 2.04 (0.66-6.32)
20 Baseline .61 16 Baseline .86
1.46 (0.34-6.31) 1.15 (0.26-5.05)
19 Baseline .64 15 Baseline .22
0.80 (0.32-2.04) 0.53 (0.19-1.46)
20 Baseline .30 16 Baseline .25
1.92 (0.56-6.57) 2.40 (0.55-10.58)
47 20 Baseline .01 16 Baseline <.01
3.00 (1.24-7.25) 3.98 (1.47-10.74)
20 Baseline .32 16 Baseline .12
0.64 (0.26-1.56) 0.43 (0.15-1.25)
I, confidence interval; DLBCL, diffuse large B cell lymphoma.; CR, com-
Biol Blood Marrow Transplant 16:1302-1308, 2010 1307HIV Status and Transplantationpatients compared with their HIV-negative counter-
parts. A multicenter case controlled study from Eu-
rope supports this [21]. A registry-based study of 18
centers in Europe looked at 53 patients with HIV-
associated NHL and Hodgkin lymphoma who under-
went autologous transplant in the era of HAART and
compared them to controls matched for histology,
stage at diagnosis, nonage-adjusted International
Prognostic Index (IPI) (NHL patients), and disease
status at ASCT. Days to neutrophil engraftment
were identical in both groups at 11 days. OS was
61.5% for HIV-positive patients and 70% for the
HIV-negative controls (P 5 NS). The main cause of
death was relapse in both groups, although there was
a not statistically significant difference in NRM in
the HIV-positive group because of bacterial infections.
Our study, although encompassing a smaller num-
ber of patients, confirms the European series, and
furthermore, has the advantage that it is a single-
institution series with the standard of care and patient
selection identical for the HIV-positive cases as well as
the HIV-negative control. The longer follow-up in
our series allows further evaluation of the potential
for late effects of HIV infection on transplant out-
come. OS was the same in both cohorts, which were
treated identically. Interestingly, despite the inclusion
of more potentially high-risk patients, those with high-
grade lymphomas in the HIV-positive cohort, PFS was
not statistically different between the groups. Some-
what akin to this, in the European case-controlled
series, the difference in CI of relapse for both
cohorts was not statistically significant (29% for HIV
positive and 42% for HIV negative), but there was
a more favorable trend in the HIV-positive group [21].
These studies, therefore, lay the groundwork for
the idea that perhaps HIV is not the ultimate arbiter
to poor transplant outcome for patients with NHL.
The intriguing trend toward lower relapse in the
HIV-positive group of patients also raises many ques-
tions about the effect of transplant on the underlying
HIV infection. Perhaps transplant is also resetting
the clock on the immunologic effects of HIV, either
by depleting the HIV reservoir or by its alterations
on the T cell reconstitution. Future studies are
planned to address these issues. For example, in
HIV-positive patients with an undetectable viral load
by conventional assays, persistent viremia as low as sin-
gle copies/mL can be measured by PCR. It remains
unclear whether this low level viremia is because of
the death of previously infected cells or due to ongoing
viral replication. It is possible that high-dose chemo-
therapy depletes the cells in the reservoir that harbored
latent virus and, therefore, single-copy polymerase
chain reaction (PCR) levels posttransplant would
reflect this. Other genotypic effects may also come
into play. Future correlative studies addressing the
questions of viral reservoir, CCR5 status, andimmune reconstitution are being planned as part of
the BMT CTN national study of ASCT in HIV
NHL. This study will also use the completed BMT
CTN trial of BEAM versus Bexxar BEAM condition-
ing with ASCT in HIV-negative NHL as a compara-
tor. Hopefully, this coordinated effort through the
transplant centers in the United States will encourage
more physicians to consider transplant for their NHL
patients regardless of HIV status. In 1997, 88% of
transplant centers excluded patients with HIV infec-
tion from solid-organ transplantation [22]. This bias
is slowly changing. Our data supports that HIV
infection did not lead to inferior long-term outcome
post-ASCT. Perhaps we should soon challenge the
final paradigm of excluding patients with
well-controlled HIV from ASCT clinical trials.ACKNOWLEDGMENTS
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